Amicus Therapeutics Announces First Quarter 2024 Financial Results and Corporate Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Amicus Therapeutics (FOLD) PT Lowered to $13 at BofA Securities
May 10, 2024 5:27 AM EDTBofA Securities analyst Tazeen Ahmad lowered the price target on Amicus Therapeutics (NASDAQ: FOLD) to $13.00 (from $14.00) while maintaining a Buy rating.
The analyst comments "FOLD reported 1Q Pombiliti+Opfolda (P&O) sales of $11mn and provided FY24 sales guidance of $62-67mn.... More
Amicus Therapeutics (FOLD) PT Lowered to $19 at Morgan Stanley
May 9, 2024 12:03 PM EDTMorgan Stanley analyst Jeffrey Hung lowered the price target on Amicus Therapeutics (NASDAQ: FOLD) to $19.00 (from $20.00) while maintaining a Underweight rating.
The analyst comments "1Q earnings were in line with Street expectations for Galafold and below on Pombiliti + Opfolda (P+O). The company... More
